Arabic Arabic English English French French German German
dark

AbbVie, REGENXBIO Partner on Potential One-Time Treatment for Wet AMD

​The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

ClearDATA Partners with Interlace Health to Safeguard Data for Zero-Touch Patient Intake Solution

Next Post

Transgene Announces Upcoming Investor Meetings – Sep 13, 2021

Related Posts
Total
0
Share